Alkermes (ALKS) Gains from Investment Securities (2023 - 2026)
Alkermes (ALKS) posted quarterly Gains from Investment Securities of $26.4 million for Q2 2026, up 1220.7% quarter-over-quarter from $2.0 million in Q2 2023.
Alkermes (ALKS) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Gains from Investment Securities for 2 consecutive years, with $26.4 million the latest figure, recorded in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.41 Mn |
| Jun 30, 2026 | 26.41 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 2.00 Mn |